{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:45:53Z","timestamp":1784591153905,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.dsx.2020.09.030","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T13:08:54Z","timestamp":1601298534000},"page":"1913-1919","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3177-2129","authenticated-orcid":false,"given":"Evangelia","family":"Makri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis","family":"Goulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraskevi","family":"Papaioannidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7345-7912","authenticated-orcid":false,"given":"Zoe A.","family":"Efstathiadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotini","family":"Adamidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9232-4042","authenticated-orcid":false,"given":"Stergios A.","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2020.09.030_bib1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2174\/1570161117666190405164313","article-title":"Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block","volume":"18","author":"Athyros","year":"2020","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.dsx.2020.09.030_bib2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.23736\/S0391-1977.16.02563-3","article-title":"Adipose tissue, obesity and non-alcoholic fatty liver disease","volume":"42","author":"Polyzos","year":"2017","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.dsx.2020.09.030_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dsx.2020.09.030_bib4","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1080\/14656566.2016.1225727","article-title":"Emerging and future therapies for nonalcoholic steatohepatitis in adults","volume":"17","author":"Mintziori","year":"2016","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.dsx.2020.09.030_bib5","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.metabol.2015.12.009","article-title":"Nonalcoholic fatty future disease","volume":"65","author":"Polyzos","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.dsx.2020.09.030_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.metabol.2013.10.010","article-title":"Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease","volume":"63","author":"Polyzos","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.dsx.2020.09.030_bib7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1055\/a-0713-1330","article-title":"Noninvasive liver fibrosis tests in patients with nonalcoholic fatty liver disease: an external validation cohort","volume":"51","author":"Polyzos","year":"2019","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.dsx.2020.09.030_bib8","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008179","article-title":"Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis","volume":"96","author":"Dai","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.dsx.2020.09.030_bib9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jdiacomp.2012.12.005","article-title":"Potential of incretin-based therapies for non-alcoholic fatty liver disease","volume":"27","author":"Samson","year":"2013","journal-title":"J\u00a0Diabet Complicat"},{"key":"10.1016\/j.dsx.2020.09.030_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/jgh.13026","article-title":"Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"31","author":"Carbone","year":"2016","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.dsx.2020.09.030_bib11","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dsx.2020.09.030_bib12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/apt.14172","article-title":"Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population","volume":"46","author":"Yip","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dsx.2020.09.030_bib13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12944-019-0986-7","article-title":"Triglycerides to high-density lipoprotein cholesterol ratio as a surrogate for nonalcoholic fatty liver disease: a cross-sectional study","volume":"18","author":"Fan","year":"2019","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.dsx.2020.09.030_bib14","first-page":"477","article-title":"APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD\/NASH","volume":"101","author":"Kruger","year":"2011","journal-title":"S\u00a0Afr Med J"},{"key":"10.1016\/j.dsx.2020.09.030_bib15","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"McPherson","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.dsx.2020.09.030_bib16","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.dsx.2020.09.030_bib17","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0016-5085(00)70364-7","article-title":"Liver fibrosis in overweight patients","volume":"118","author":"Ratziu","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dsx.2020.09.030_bib18","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/gut.2007.146019","article-title":"Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease","volume":"57","author":"Harrison","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.dsx.2020.09.030_bib19","first-page":"800","article-title":"Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease","volume":"9","author":"Feng","year":"2017","journal-title":"J\u00a0Diabetes"},{"key":"10.1016\/j.dsx.2020.09.030_bib20","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/dom.13007","article-title":"Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: a pilot randomized trial","volume":"19","author":"Khoo","year":"2017","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2020.09.030_bib21","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/MCG.0b013e31824587e0","article-title":"Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease","volume":"46","author":"Polyzos","year":"2012","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.dsx.2020.09.030_bib22","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.dsx.2020.09.030_bib23","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1007\/s00125-016-4100-7","article-title":"Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial","volume":"59","author":"Smits","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.dsx.2020.09.030_bib24","doi-asserted-by":"crossref","DOI":"10.1100\/2012\/496453","article-title":"The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone","volume":"2012","author":"Ohki","year":"2012","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.dsx.2020.09.030_bib25","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.14309\/ajg.0000000000000388","article-title":"Histologic findings of advanced fibrosis and cirrhosis in patients with nonalcoholic fatty liver disease who have normal aminotransferase levels","volume":"114","author":"Gawrieh","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dsx.2020.09.030_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005325","article-title":"Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes","volume":"4","author":"Gluud","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.dsx.2020.09.030_bib27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/apt.12149","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program","volume":"37","author":"Armstrong","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dsx.2020.09.030_bib28","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1210\/jc.2014-3794","article-title":"Effect of vildagliptin on hepatic steatosis","volume":"100","author":"Macauley","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.dsx.2020.09.030_bib29","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/dom.12680","article-title":"Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy","volume":"18","author":"Dutour","year":"2016","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2020.09.030_bib30","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clinre.2016.11.009","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"41","author":"Dong","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.dsx.2020.09.030_bib31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3748\/wjg.v23.i1.141","article-title":"Sitagliptin in patients with non-alcoholic steatohepatitis: a randomized, placebo-controlled trial","volume":"23","author":"Joy","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dsx.2020.09.030_bib32","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2337\/dc14-2548","article-title":"Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial","volume":"38","author":"Tang","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2020.09.030_bib33","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/hep.23789","article-title":"Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data","volume":"52","author":"Ghouri","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dsx.2020.09.030_bib34","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2020.09.030_bib35","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1478-3231.2011.02482.x","article-title":"Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors","volume":"31","author":"Leite","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.dsx.2020.09.030_bib36","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Vilsboll","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.dsx.2020.09.030_bib37","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.dsx.2020.09.030_bib38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402120303829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402120303829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:21:34Z","timestamp":1761729694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402120303829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1871402120303829"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2020.09.030","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2020.09.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}